[The prognostic value of modified quantitative classification and expression of monoclonal antibodies against PCNA in laryngeal neoplasm (introduction)].
In clinical practice there are no sufficient histopathological and immunohistochemical parameters to predicting progression of laryngeal cancer. We applied the new quantitative Anertoha, Blatsakisa and Luny cancer classification and expression of PCNA (proliferating cell nuclear antigen) to clinical findings to appreciate prognosis in laryngeal cancer.